Perspectives | Apellis Pharmaceuticals, Inc.

Skip to main navigation

Loading...

About Us
Our Science
For Patients
- For Patients
- PNH
- Geographic Atrophy
- C3G
- CAD
- Expanded Access
Careers
- Careers
- Opportunities
Investors & Media
Contact Us
Twitter
LinkedIn

Investors & Media

Home / Investors & Media / Perspectives Perspectives

Perspectives

Rare Disease Report

December 6, 2018

Potential Paroxysmal Nocturnal Hemoglobinuria Treatment, APL-2, Shows Positive …

Insider Louisville

December 4, 2018

Apellis shares spike on promising new drug data

BioWorld

November 21, 2018

Appointments and advancements

Endpoints

November 21, 2018

Gurnet Point-backed Auregen taps Amgen vet to lead; Ex-Roche RNA chief takes CE…

BioCentury

November 21, 2018

MANAGEMENT TRACKS: BERGENBIO, ALZAMEND

Louisville Business First

November 20, 2018

Apellis hires veteran biotech exec for new C-suite role

Seeking Alpha

November 20, 2018

Apellis Pharmaceuticals appoints Adam Townsend as Chief Commercial Officer

Retina News

October 30, 2018

APELLIS BEGINS PHASE 3 TRIALS FOR COMPLEMENT INHIBITION IN GA

Healio

September 16, 2018

OSN’s top news of the week

BioWorld

September 13, 2018

Clinical data for Sept. 12, 2018

Pagination

Current page 1
Page 2
Page 3
Page 4
Next page
Last page

Print Page Email Alerts RSS Feeds Contact IR

© Apellis Pharmaceuticals 2020. |

Privacy Policy

This website is intended for residents of the U.S.